Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aileron Therapeutics, Inc., a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, announced today the publication of preclinical data on ATSP-7041, a potent and selective stapled peptide re-activator of the wild type p53 tumor suppressor protein. P53, known as “the guardian of the genome” because it repairs damaged DNA or triggers cell death in pre-cancerous cells, is one of the most important known tumor suppressors, as it is shown to be inactivated in virtually all human cancers. As 50% of all cancers circumvent p53’s protective mechanisms by the over-expression of the inhibitory proteins MDM2 and MDMX, Aileron’s stapled peptide is novel in that it can selectively bind to and inhibit both proteins equally and, thereby, restore the p53 function. The research, published in Proceedings of the National Academy of Sciences (PNAS), provides the first detailed publication by Aileron of one of its cell penetrating peptides that is a precursor molecule to one that the company is developing for the treatment of both liquid and solid tumors. The paper, entitled “Stapled a-Helical Peptide Drug Development: A Potent Dual Inhibitor of MDM2 and MDMX for p53-Dependent Cancer Therapy,” expands on data reported by the company in poster presentations at the 2012 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics and the 2013 International MDM2 workshop in Cambridge, England.
Help employers find you! Check out all the jobs and post your resume.
